323 related articles for article (PubMed ID: 37917364)
1. The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma.
Kou L; Xie X; Chen X; Li B; Li J; Li Y
Cancer Immunol Immunother; 2023 Dec; 72(12):3953-3969. PubMed ID: 37917364
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitor resistance in hepatocellular carcinoma.
Wang Z; Wang Y; Gao P; Ding J
Cancer Lett; 2023 Feb; 555():216038. PubMed ID: 36529238
[TBL] [Abstract][Full Text] [Related]
3. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
4. Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma.
Chami P; Diab Y; Khalil DN; Azhari H; Jarnagin WR; Abou-Alfa GK; Harding JJ; Hajj J; Ma J; El Homsi M; Reyngold M; Crane C; Hajj C
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069095
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data.
Harkus U; Wankell M; Palamuthusingam P; McFarlane C; Hebbard L
Semin Cancer Biol; 2022 Nov; 86(Pt 3):799-815. PubMed ID: 35065242
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition.
Tao S; Liang S; Zeng T; Yin D
Front Immunol; 2022; 13():1043667. PubMed ID: 36685594
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma.
Akbulut Z; Aru B; Aydın F; Yanıkkaya Demirel G
Front Immunol; 2024; 15():1379622. PubMed ID: 38638433
[TBL] [Abstract][Full Text] [Related]
8. The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma.
Liu L; Qin S; Zhang Y
Target Oncol; 2021 Mar; 16(2):153-163. PubMed ID: 33528759
[TBL] [Abstract][Full Text] [Related]
9. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy.
Li Q; Han J; Yang Y; Chen Y
Front Immunol; 2022; 13():1070961. PubMed ID: 36601120
[TBL] [Abstract][Full Text] [Related]
10. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
11. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Bai J; Liang P; Li Q; Feng R; Liu J
Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
[TBL] [Abstract][Full Text] [Related]
12. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma.
Chen Y; Wang X; Deng X; Zhang Y; Liao R; Li Y; Yang H; Chen K
Front Immunol; 2021; 12():676922. PubMed ID: 34335575
[TBL] [Abstract][Full Text] [Related]
13. Development of a TMErisk model based on immune infiltration in tumour microenvironment to predict prognosis of immune checkpoint inhibitor treatment in hepatocellular carcinoma.
Yan ZJ; Yu CT; Chen L; Wang HY
Brief Bioinform; 2023 Mar; 24(2):. PubMed ID: 36882021
[TBL] [Abstract][Full Text] [Related]
14. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
Rizzo A; Brandi G
Cancer Treat Res Commun; 2021; 27():100328. PubMed ID: 33549983
[TBL] [Abstract][Full Text] [Related]
15. Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
Carloni R; Rizzo A; Ricci AD; Frega G; Federico AD; Palloni A; Marco MD; Gadaleta-Caldarola G; Brandi G
Future Oncol; 2022 Mar; 18(8):1023-1034. PubMed ID: 35109664
[TBL] [Abstract][Full Text] [Related]
16. Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma.
Ruff SM; Manne A; Cloyd JM; Dillhoff M; Ejaz A; Pawlik TM
Curr Oncol; 2023 Jun; 30(6):5863-5875. PubMed ID: 37366922
[TBL] [Abstract][Full Text] [Related]
17. Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma.
Sharma R; Motedayen Aval L
Front Immunol; 2021; 12():652007. PubMed ID: 33790915
[TBL] [Abstract][Full Text] [Related]
18. Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma.
Chen X; Kou L; Xie X; Su S; Li J; Li Y
Immunology; 2024 May; 172(1):21-45. PubMed ID: 38214111
[TBL] [Abstract][Full Text] [Related]
19. Ferroptosis, pyroptosis and necroptosis in hepatocellular carcinoma immunotherapy: Mechanisms and immunologic landscape (Review).
Liu RJ; Yu XD; Yan SS; Guo ZW; Zao XB; Zhang YS
Int J Oncol; 2024 Jun; 64(6):. PubMed ID: 38757345
[TBL] [Abstract][Full Text] [Related]
20. Nanomedicines for reversing immunosuppressive microenvironment of hepatocellular carcinoma.
Pan X; Ni S; Hu K
Biomaterials; 2024 Apr; 306():122481. PubMed ID: 38286109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]